Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solution for Women With Breast Cancer Undergoing Chemotherapy (iCareBreast+): A Pilot Study Research Proposal

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The overall aim of the study is to evaluate the feasibility, acceptability and preliminary effects of the next iteration of iCareBreast+, an innovative breast care e-support intervention programme, by refining existing contents and building new contents based on comprehensive assessment of breast cancer women's needs and preferences among breast cancer patients undergoing chemotherapy. The specific objectives of this study are: 1. To develop a new iteration of an innovative smartphone-based self-care solution for patients with breast cancer undergoing chemotherapy (iCareBreast+); 2. To assess the feasibility and acceptability of iCareBreast+; and 3. To explore the preliminary effects of iCareBreast+ on the primary outcome of self-efficacy, and knowledge of breast cancer treatment, as well as secondary outcomes including anxiety, depression, health-related quality of life (HRQoL), social support and satisfaction with oncologic care.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 21
Maximum Age: 100
Healthy Volunteers: f
View:

⁃ Women who:

• are the age of 21 years old and above at the point of recruitment;

• are diagnosed with stage 1-3 breast cancer;

• will undergo chemotherapy first time (initiating or up to #4 cycles of chemo is acceptable);

• can speak, read and write in English or Mandarin; and

• has access to and able to use smart phone.

Locations
Other Locations
Singapore
National Cancer Centre, Singapore
RECRUITING
Singapore
Contact Information
Primary
Dr Ryan Shea YC Tan, MBBS, MRCP(UK), MMed
ryan.shea.tan.y.c@singhealth.com.sg
+65 64368000
Backup
Bernard JG Chua, MBBS (Hons)(Aus), MRCP (UK)
bernard.chua.j.g@singhealth.com.sg
+65 64368000
Time Frame
Start Date: 2025-05-23
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 40
Treatments
Experimental: Control Group
Experimental: Intervention Group
Related Therapeutic Areas
Sponsors
Collaborators: Buddy Healthcare Ltd OY
Leads: National Cancer Centre, Singapore

This content was sourced from clinicaltrials.gov